Background: Cartilage intermediate layer protein 2 (CILP2) is a monomeric glycoprotein that is mostly expressed in the intermediate zone of articular cartilage and can be detected in the extracellular matrix (ECM). The level of CILP2 in serum and its quantity on the articular cartilage surface and throughout the articular cartilage indicates the potential utility of CILP2 for investigation as a biomarker for determining cartilage deterioration in joint disorders. The CILP2 measurement of changes in cartilage biomarkers may be an effective and sensitive tool for detecting the early development of knee osteoarthritis (KOA) in people at risk for KOA. Changes in CILP2 levels may be beneficial for the early diagnosis of KOA, as CILP2 appears to be linked to cartilage thickness reduction in people who are more likely to develop KOA. Platelet rich plasma (PRP) effectiveness of transforming growth factor, platelet-derived growth factor, and the vascular endothelial growth factor is thought to be related to their release. Because of their capacity to increase matrix formation,growth factors have been widely researched for OA and cartilage regeneration. Hyaluronic acid (HA) is a glycosaminoglycan polymer composed of N-acetyl glucosamine and D-glucuronic acid disaccharide molecules. Early embryonic development, inflammatory, wound repair, cell differentiation, and viscoelasticity are all affected by HA, and other biological processes The study was aimed to evaluate effecte of CILP2 levels after intraarticular injecting pure platelet-rich plasma and hyaluronic acid into patients with early knee osteoarthritis.

Materials and Methods: BT LAB kits were used to assess the serum CILP2 level. The experimental investigation included 18 control groups, 10 HA injections, and 21 pure PRP injections. age ranged from 35 to 75. The study was exluded all individuals with advanced osteoarthritis in the knee, COVID-19, diabetes, and autoimmune diseases. the time frame running from November 2021 until June 2022. Other variables in our research were age, gender, family history, use of antihypertensive medications or medications for other disorders, and body mass index (BMI).

Results: The findings of this study demonstrate elevated CILP2 levels in patients with early KOA before treatments injection compared with the healthy control. After treatments injection, the level of CILP2 was decreased compared with before injection.

Conclusions: CILP2 could be one of the prognostic signs of early KOA.

Keywords: Osteoarthritis; CILP2; Joints; Arthritis, PRP; Hyaluronic acid